EGFR and plasma cell myeloma: In this study, our results elucidate a new mechanism by which myeloma-MSC interaction upregulates the production of osteolytic cytokines through the integrin α6/laminin8/EGFR signaling and offer a potential strategy for targeted treatment of myeloma-associated bone disease.